GE HealthCare Reports Mixed Q1 Results, Lowers Full-Year Profit & Free Cash Flow Guidance, Closes Intelerad Acquisition

summarizeSummary

GE HealthCare reported Q1 revenue growth but lower profits, leading to a reduction in full-year profit and free cash flow guidance due to inflation, while also announcing the completion of its $2.3 billion Intelerad acquisition and a $100 million share repurchase.

check_boxKey Events

• Mixed Q1 2026 Financial Results

  Reported Q1 revenues of $5.1 billion, up 7.4% (2.9% organic), but net income attributable to GE HealthCare decreased to $389 million from $564 million year-over-year. Diluted EPS was $0.85, down from $1.23, and Adjusted EPS was $0.99, down from $1.01, impacted by a PDx supplier issue and increased inflation.

• Reduced Full-Year Profit and Free Cash Flow Guidance

  Lowered full-year 2026 Adjusted EBIT margin guidance to 15.4%-15.7% (from 15.8%-16.1%), Adjusted EPS to $4.80-$5.00 (from $4.95-$5.15), and Free Cash Flow to approximately $1.6 billion (from $1.7 billion), primarily due to more pronounced inflation assumptions. Organic revenue growth guidance remains unchanged at 3.0%-4.0%.

• Completed $2.3 Billion Intelerad Acquisition

  Finalized the acquisition of Intelerad for $2.3 billion, a strategic move to advance cloud-enabled enterprise imaging across care settings. This follows the proposed acquisition mentioned in the 10-K filed on 2026-02-04.

• Executed Share Repurchase Program

  Repurchased 1.4 million shares for a total consideration of $100 million, part of the existing share repurchase program detailed in the 10-K filed on 2026-02-04. This action occurred while the stock is trading below its 52-week low.

auto_awesomeAnalysis

GE HealthCare reported mixed first-quarter 2026 financial results, with strong revenue growth driven by Pharmaceutical Diagnostics and Advanced Visualization Solutions, but a decline in net income and EPS year-over-year. The company's profitability was impacted by a discrete supplier issue and increased inflation in memory chips, oil, and freight costs. Consequently, GE HealthCare reduced its full-year 2026 Adjusted EBIT margin, Adjusted EPS, and Free Cash Flow guidance, citing more pronounced inflation assumptions, while maintaining its organic revenue growth outlook. This guidance cut is a significant negative signal, especially as the stock is currently trading below its 52-week low. On a positive strategic note, the company completed its previously announced $2.3 billion acquisition of Intelerad, which is expected to advance its cloud-enabled enterprise imaging solutions. Additionally, the company repurchased $100 million in shares, a positive sign of capital allocation and management confidence given the current stock price levels.